FY2025 EPS Estimates for Globus Medical Lifted by Analyst

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Globus Medical in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings per share of $3.43 for the year, up from their prior estimate of $3.42. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $0.97 EPS.

A number of other research analysts also recently commented on GMED. Royal Bank of Canada boosted their target price on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th. Stifel Nicolaus boosted their price target on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Roth Mkm raised their price objective on shares of Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 17th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $80.00 to $97.00 in a research note on Thursday, January 9th. Finally, Morgan Stanley upgraded shares of Globus Medical from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average price target of $96.91.

Globus Medical Stock Down 1.0 %

Globus Medical stock opened at $92.42 on Thursday. Globus Medical has a 12 month low of $49.33 and a 12 month high of $93.67. The stock has a market cap of $12.59 billion, a P/E ratio of 137.94, a P/E/G ratio of 1.76 and a beta of 1.19. The company’s fifty day simple moving average is $84.64 and its 200-day simple moving average is $76.45.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.65 by $0.18. The business had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period last year, the company posted $0.57 earnings per share.

Insider Transactions at Globus Medical

In related news, SVP Kelly Huller sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $81.01, for a total transaction of $405,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Keith W. Pfeil sold 14,167 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,667 shares of company stock worth $6,674,554. Company insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several large investors have recently added to or reduced their stakes in the company. Select Equity Group L.P. bought a new stake in shares of Globus Medical during the second quarter valued at approximately $91,711,000. Millennium Management LLC increased its holdings in Globus Medical by 1,171.5% in the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after buying an additional 1,256,570 shares during the period. ArrowMark Colorado Holdings LLC acquired a new position in shares of Globus Medical in the 3rd quarter valued at $43,947,000. Lord Abbett & CO. LLC bought a new position in shares of Globus Medical during the 3rd quarter worth about $37,948,000. Finally, Parsifal Capital Management LP boosted its position in shares of Globus Medical by 50.5% during the 3rd quarter. Parsifal Capital Management LP now owns 1,350,553 shares of the medical device company’s stock valued at $96,619,000 after acquiring an additional 453,053 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.